Overcoming BCRP-mediated multidrug resistance

Drugs of the Future

Volumn 33, Issue 6, 2008, Pages 533-542

  Florin, A ^a   Boutonnat, J ^a   Boumendjel, Ahcene ^a  

^a Laboratoire de Pharmacochimie   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACRIDONE DERIVATIVE; ANTIVIRUS AGENT; APIGENIN; BIOCHANIN A; BREAST CANCER RESISTANCE PROTEIN; BREAST CANCER RESISTANCE PROTEIN INHIBITOR; CANERTINIB; CHRYSIN; DELAVIRDINE; DIETHYLSTILBESTROL; EFAVIRENZ; EKI 785; FLAVONOID; FUMITREMORGIN C; GEFITINIB; GENISTEIN; IMATINIB; KAEMPFEROL; KO 132; LOPINAVIR; NELFINAVIR; PIPERAZINE DERIVATIVE; PROTEIN INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; TAMOXIFEN; TECTOCHRYSIN; TOPOTECAN; UNINDEXED DRUG;

BINDING COMPETITION; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; CYTOTOXICITY TEST; DRUG BIOAVAILABILITY; DRUG POTENCY; DRUG POTENTIATION; DRUG STRUCTURE; ENZYME ACTIVITY; ENZYME INHIBITION; GASTROINTESTINAL STROMAL TUMOR; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYDROPHOBICITY; LOW DRUG DOSE; MULTIDRUG RESISTANCE; NEUROTOXICITY; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; QUANTITATIVE STRUCTURE ACTIVITY RELATION; REVIEW; TREMOR; UNSPECIFIED SIDE EFFECT; VIRUS RESISTANCE;

EID: 51749120319     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2008.033.06.1192674     Document Type: Review

References (61)

1. Ambudkar, S.V., Dey, S., Hrycyna, C.A., Ramachandra, M., Pastan, I., Gottesman, M.M. Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu Rev Pharmacol Toxicol 1999, 39: 361-98.
2. Molinari, A., Calcabrini, A., Meschini, S. et al. Subcellular detection and localization of the drug transporter P-glycoprotein in cultured tumor cells. Curr Protein Pept Sci 2002, 3(6): 653-70.
3. Juliano, R.L., Ling, V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta 1976, 455(1): 152-62.
4. Cole, S.P., Bhardwaj, G., Gerlach, J.H. et al. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 1992, 258(5088): 1650-4.
5. Doyle, L.A., Yang, W., Abruzzo, L.V., Krogmann, T., Gao, Y., Rishi, A.K., Ross, D.D. A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc Natl Acad Sci USA 1998, 95(26): 15665-70.
6. Allikmets, R., Schriml, L.M., Hutchinson, A., Romano-Spica, V., Dean, M. A human placenta-specific ATP-binding cassette gene (ABCP) on chromosome 4q22 that is involved in multidrug resistance. Cancer Res 1998, 58(23): 5337-9.
7. Miyake, K., Mickley, L., Litman, T. et al. Molecular cloning of cDNAs which are highly overexpressed in mitoxantrone-resistant cells: Demonstration of homology to ABC transport genes. Cancer Res 1999, 59(1): 8-13.
8. Ross, D.D., Yang, W,, Abruzzo, L.V. et al. Atypical multidrug resistance: Breast cancer resistance protein messenger RNA expression in mitoxantrone-selected cell lines. J Natl Cancer Inst 1999, 91(5): 429-33.
9. Knutsen, T., Rao, V.K., Ried, T. et al. Amplification of 4q21-q22 and the MXR gene in independently derived mitoxantrone-resistant cell lines. Genes Chromosomes Cancer 2000, 27(1): 110-6.
10. Szakacs, G., Annereau, J.P., Lababidi, S. et al. Predicting drug sensitivity and resistance: Profiling ABC transporter genes in cancer cells. Cancer Cell 2004, 6(2): 129-37.
11. Gottesman, M.M., Fojo, T., Bates, S.E. Multidrug resistance in cancer: Role of ATP-dependent transporters. Nat Rev Cancer 2002, 2(1): 48-58.
12. Leslie, E.M., Deeley, R.G., Cole, S.P. Multidrug resistance proteins: Role of P-glycoprotein, MRP1, MRP2, and BCRP (ABCG2) in tissue defense. Toxicol Appl Pharmacol 2005, 204(3): 216-37.
13. Doyle, L.A., Ross, D. D. Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2). Oncogene 2003, 22(47): 7340-58.
14. Litman, T., Brangi, M., Hudson, E. et al. The multidrug-resistant phenotype associated with overexpression of the new ABC half-transporter, MXR (ABCG2). J Cell Sci 2000, 113(Pt. 11): 2011-21.
15. Mao, Q., Unadkat, J.D. Role of the breast cancer resistance protein (ABCG2) in drug transport. AAPS J 2005, 7(1): E118-33.
16. Tusnady, G.E., Sarkadi, B., Simon, I., Varadi, A. Membrane topology of human ABC proteins. FEBS Lett 2006, 580(4):1017-22.
17. Kage, K., Fujita, T., Sugimoto, Y. Role of Cys-603 in dimer/oligomer formation of the breast cancer resistance protein BCRP/ABCG2. Cancer Sci 2005, 96(12): 866-72.
18. Ozvegy-Laczka, C., Koblos, G., Sarkadi, B., Varadi, A. Single amino acid (482) variants of the ABCG2 multidrug transporter: Major differences in transport capacity and substrate recognition. Biochim Biophys Acta 2005, 1668(1): 53-63.
19. Honjo, Y., Hrycyna, C.A., Yan, Q.W. et al. Acquired mutations in the MXR/BCRP/ABCP gene alter substrate specificity in MXR/BCRP/ ABCP-overexpressing cells. Cancer Res 2001, 61(18): 6635-9.
20. Ozvegy, C., Váradi, A., Sarkadi, B. Characterization of drug transport, ATP hydrolysis, and nucleotide trapping by the human ABCG2 multidrug transporter. Modulation of substrate specificity by a point mutation. J Biol Chem 2002, 277(50): 47980-90.
21. Robey, R.W., Honjo, Y., Morisaki, K. et al. Mutations at amino-acid 482 in the ABCG2 gene affect substrate and antagonist specificity. Br J Cancer 2003, 89(10): 1971-8.
22. Chen, Z.S., Robey, R.W., Belinsky, M.G. et al. Transport of methotrexate, methotrexate polyglutamates, and 17beta-estradiol 17-(beta-D-glucuronide) by ABCG2: Effects of acquired mutations at P482 on methotrexate transport. Cancer Res 2003, 63(14): 4048-54.
23. Robey, R.W., Polgar, O., Deeken, J., To, K.W., Bates, S.E. ABCG2: Determining its relevance in clinical drug resistance. Cancer Metastasis Rev 2007, 26(1): 39-57.
24. Mohrmann, K., van Eijndhoven, M.A., Schinkel, A.H., Schellens, J.H. Absence of N-linked glycosylation does not affect plasma membrane localization of breast cancer resistance protein (BCRP/ABCG2). Cancer Chemother Pharmacol 2005, 56(4): 344-50.
25. Lee, C.G., Ramachandra, M., Jeang, K.T., Martin, M.A., Pastan, I., Gottesman, M.M. Effect of ABC transporters on HIV-1 infection: Inhibition of virus production by the MDR1 transporter. FASEB J 2000, 14(3): 516-22.
26. Wang, X., Baba, M. The role of breast cancer resistance protein (BCRP/ ABCG2) in cellular resistance to HIV-1 nucleoside reverse transcriptase inhibitors. Antivir Chem Chemother 2005, 16(4): 213-6.
27. Weiss, J., Rose, J., Storch, C.H., Ketabi-Kiyanvash, N., Sauer, A., Haefeli, W.E., Efferth, T. Modulation of human BCRP (ABCG2) activity by anti-HIV drugs. J Antimicrob Chemother 2007, 59(2): 238-45.
28. Breedveld, P., Pluim, D., Cipriani, G., Wielinga, P., van Tellingen, O., Schinkel, A.H., Schellens, J.H. The effectof Bcrp1 (Abcg2) on the in vivo pharmacokinetics and brain penetration of imatinib mesylate (Gleevec): Implications for the use of breast cancer resistance protein and P-glycoprotein inhibitors to enable the brain penetration of imatinib in patients. Cancer Res 2005, 65(7): 2577-82.
29. Burger, H., van Tol, H., Boersma, A.W., Brok, M., Wiemer, E.A., Stoter, G., Nooter, K. Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump. Blood 2004, 104(9): 2940-2.
30. Erlichman, C., Boerner, S.A., Hallgren, C.G. et al. The HER tyrosine kinase inhibitor CI1033 enhances cytotoxicity of 7-ethyl-10-hydroxycamptothecin and topotecan by inhibiting breast cancer resistance protein-mediated drug efflux. Cancer Res 2001, 61(2): 739-48.
31. Houghton, P.J., Germain, G.S., Harwood, F.C., Schuetz, J.D., Stewart, C.F., Buchdunger, E., Traxler, P. Imatinib mesylate is a potent inhibitor of the ABCG2 (BCRP) transporter and reverses resistance to topotecan and SN-38 in vitro. Cancer Res 2004, 64(7): 2333-7.
32. Liu, H., Cheng, D., Weichel, A.K. et al. Cooperative effect of gefitinib and fumitremorgin C on cell growth and chemosensitivity in estrogen receptor alpha negative fulvestrant-resistant MCF-7 cells. Int J Oncol 2006, 29(5): 1237-46.
33. Ozvegy-Laczka, C., Hegedus, T., Várady, G. et al. High-affinity interaction of tyrosine kinase inhibitors with the ABCG2 multidrug transporter. Mol Pharmacol 2004, 65(6): 1485-95.
34. Yanase, K., Tsukahara, S., Asada, S., Ishikawa, E., Imai, Y., Sugimoto, Y. Gefitinib reverses breast cancer resistance protein-mediated drug resistance. Mol Cancer Ther 2004, 3(9): 1119-25.
35. Zhang, S., Yang, X., Morris, M.E. Combined effects of multiple flavonoids on breast cancer resistance protein (ABCG2)-mediated transport. Pharm Res 2004, 21(7): 1263-73.
36. Zhang, S., Yang, X., Morris, M.E. Flavonoids are inhibitors of breast cancer resistance protein (ABCG2)-mediated transport. Mol Pharmacol 2004, 65(5): 1208-16.
37. Katayama, K., Masuyama, K., Yoshioka, S., Hasegawa, H., Mitsuhashi, J., Sugimoto, Y. Flavonoids inhibit breast cancer resistance protein-mediated drug resistance: Transporter specificity and structure-activity relationship. Cancer Chemother Pharmacol 2007, 60(6): 789-97.
38. Ahmed-Belkacem, A., Pozza, A., Munoz-Martinez, F. et al. Flavonoid structure-activity studies identify 6-prenylchtysin and tectochrysin as potent and specific inhibitors of breast cancer resistance protein ABCG2. Cancer Res 2005, 65(11): 4852-60.
39. Imai, Y., Tsukahara, S., Asada, S., Sugimoto, Y. Phytoestrogens/ flavonoids reverse breast cancer resistance protein/ABCG2-mediated multidrug resistance. Cancer Res 2004, 64(12): 4346-52.
40. Ahmed-Belkacem, A., Macalou, S., Borrelli, F., Capasso, R., Fattorusso, E., Taglialatela-Scafati, E., Di Pietro, A. Nonprenylated rotenoids, a new class of potent breast cancer resistance protein inhibitors. J Med Chem 2007, 50(8): 1933-8.
41. Dantzig, A.H., Grese, T.A., Norman, B.H., Palkowitz, A.D., Sluka, J.P., Starling, J.J., Winter, M.A. (Eli Lilly & Co.). Benzothiophene derivatives for treating resistant tumors. EP 0773217.
42. Imai, Y., Tsukahara, S., Ishikawa, E., Tsuruo, T., Sugimoto, Y. Estrone and 17beta-estradiol reverse breast cancer resistance protein-mediated multidrug resistance. Jpn J Cancer Res 2002, 93(3): 231-5.
43. Imai, Y., Asada, S., Tsukahara, S., Ishikawa, E., Tsuruo, T., Sugimoto, Y. Breast cancer resistance protein exports sulfated estrogens but not free estrogens. Mol Pharmacol 2003, 64(3): 610-8.
44. Sugimoto, Y., Tsukahara, S., Imai, Y., Ueda, K., Tsuruo, T. Reversal of breast cancer resistance protein-mediated drug resistance by estrogen antagonists and agonists. Mol Cancer Ther 2003, 2(1): 105-12.
45. Hyafil, F., Vergely, C., Du Vignaud, P., Grand-Perret, T. In vitro and in vivo reversal of multidrug resistance by GF120918, an acridonecarboxamide derivative. Cancer Res 1993, 53(19): 4595-602.
46. Allen, J.D., Van Dort, S.C., Buitelaar, M., van Tellingen, O., Schinkel, A.H. Mouse breast cancer resistance protein (Bcrp1/Abcg2) mediates etoposide resistance and transport, but etoposide oral availability is limited primarily by P-glycoprotein. Cancer Res 2003, 63(6): 1339-44.
47. Kruijtzer, C.M., Beijnen, J.H., Rosing, H et al. Increased oral bioavailability of topotecan in combination with the breast cancer resistance protein and P-glycoprotein inhibitor GF120918. J Clin Oncol 2002, 20(13): 2943-50.
48. Jonker, J.W., Smit, J.W., Brinkhuis, R.F., Maliepaard, M., Beijnen, J.H., Schellens, J.H., Schinkel, A.H. Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan. J Natl Cancer Inst 2000, 92(20): 1651-6.
49. de Bruin, M., Miyake, K., Litman, T., Robey, R., Bates, S.E. Reversal of resistance by GF120918 in cell lines expressing the ABC half-transporter, MXR. Cancer Lett 1999, 146(2): 117-26.
50. Maliepaard, M., van Gastelen, M.A., Tohgo, A. et al. Circumvention of breast cancer resistance protein (BCRP)-mediated resistance to camptothecins in vitro using non-substrate drugs or the BCRP inhibitor GF120918. Clin Cancer Res 2001, 7(4): 935-41.
51. Boumendjel, A., Macalou, S., Ahmed-Belkacem, A., Blanc, M., Di Pietro, A. Acridone derivatives: Design, synthesis and inhibition of breast cancer resistance protein ABCG2. Bioorg Med Chem 2007, 15(8): 2892-7.
52. Rabindran, S.K., He, H., Singh, M., Brown, E., Collins, K.I., Annable, T., Greenberger, L.M. Reversal of a novel multidrug resistance mechanism in human colon carcinoma cells by fumitremorgin C. Cancer Res 1998, 58(24): 5850-8.
53. Rabindran, S.K., Ross, D.D., Doyle, L.A., Yang, W., Greenberger, L.M. Fumitremorgin C reverses multidrug resistance in cells transfected with the breast cancer resistance protein. Cancer Res 2000, 60(1): 47-50.
54. Allen, J.D., van Loevezijn, A., Lakhai, J.M. et al. Potent and specific inhibition of the breast cancer resistance protein multidrug transporter in vitro and in mouse intestine by a novel analogue of fumitremorgin C. Mol Cancer Ther 2002, 1(6): 417-25.
55. Usui, T., Kondoh, M., Cui, C.B., Mayumi, T., Osada, H. Tryprostatin A, a novel and specific inhibitor of microtubule assembly. Biochem J 1998, 333(Pt. 3): 543-8.
56. Woehlecke, H., Osada, H., Herrmann, A., Lage, H. Reversal of breast cancer resistance protein mediated-drug resistance by tryprostatin A. Int J Cancer 2003, 107(5): 721-8.
57. Brooks, T., Minderman, H., O'Loughlin, K.L., Pera, P., Ojima, I., Baer, M.R., Bernacki, R.J. Taxane-based reversal agents modulate drug resistance mediated by P-glycoprotein, multidrug resistance protein, and breast cancer resistance protein. Mol Cancer Ther 2003, 2(11): 1195-205.
58. Holland, M.L., Lau, D.T., Allen, J.D., Arnold, J.C. The multidrug transporter ABCG2 (BCRP) is inhibited by plant-derived cannabinoids. Br J Pharmacol 2007, 152(5): 815-24.
59. Jin, J., Shahi, S., Kang, H.K., van Veen, H.W., Fan, T.P. Metabolites of ginsenosides as novel BCRP inhibitors. Biochem Biophys Res Commun 2006, 345(4): 1308-14.
60. Gupta, A., Unadkat, J.D., Mao, Q. Interactions of azole antifungal agents with the human breast cancer resistance protein (BCRP). J Pharm Sci 2007, 96(12): 3226-35.
61. Matsson, P., Englund, G., Ahlin, G., Bergström, C.A., Norinder, U., Artursson, P. A global drug inhibition pattern for the human ATP-binding cassette transporter breast cancer resistance protein (ABCG2). J Pharmacol Exp Ther 2007, 323(1): 19-30.